EMA Withdrawn: Sixmo (buprenorphine hydrochloride) — L. Molteni & C. dei Fratelli Alitti Società di Esercizio S.p.A.

View source ↗

Summary

EMA has withdrawn Sixmo, a buprenorphine hydrochloride injection for opioid use disorder, from the European market. The marketing authorization for this product…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid Use Disorder

Drugs mentioned

• Sixmo (buprenorphine hydrochloride)

Snippet

Status: Withdrawn. Therapeutic area: Opioid-Related Disorders. MAH: L. Molteni & C. dei Fratelli Alitti Società di Esercizio S.p.A.. Decision date: 23/05/2025